Search results
Results from the WOW.Com Content Network
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer ...
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
US FDA approves Merck's drug for kidney cancer December 14, 2023 at 5:51 PM (Reuters) -The U.S. Food and Drug Administration on Thursday approved Merck's drug belzutifan for a type of kidney cancer.
Everolimus is approved for various conditions: Advanced kidney cancer (US FDA approved in March 2009) [15] Prevention of organ rejection after renal transplant(US FDA April 2010) [16] Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (US FDA October 2010 ...
[13] [14] The capsule form was approved in the European Union for the same purpose in 2014. [11] In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer [15] [16] and the same was approved in the European Union in September of that year. [12]
For premium support please call: 800-290-4726 more ways to reach us
In April 2016 the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer [24] and the same was approved in Europe in October of that year. [ 25 ] In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer [ 26 ] and in May 2018 approval for ...
Treatment for kidney cancer depends on the type and stage of the disease. Surgery is the most common treatment as kidney cancer does not often respond to chemotherapy and radiotherapy. Surgical complexity can be estimated by the RENAL Nephrometry Scoring System. If the cancer has not spread it will usually be removed by surgery.